Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $1.1 million.

  • Gyre Therapeutics' Share-based Compensation rose 383.97% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year decrease of 56.25%. This contributed to the annual value of $831,000 for FY2024, which is 88.59% down from last year.
  • Per Gyre Therapeutics' latest filing, its Share-based Compensation stood at $1.1 million for Q3 2025, which was up 26.60% from $906,000 recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Share-based Compensation registered a high of $12.3 million during Q4 2022, and its lowest value of $11,000 during Q1 2024.
  • For the 3-year period, Gyre Therapeutics' Share-based Compensation averaged around $970,182, with its median value being $237,000 (2024).
  • In the last 5 years, Gyre Therapeutics' Share-based Compensation slumped by 94.76% in 2024 and then soared by 5,562.50% in 2025.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Share-based Compensation stood at $683,000 in 2021, then soared by 1,698.10% to $12.3 million in 2022, then crashed by 43.95% to $6.9 million in 2023, then plummeted by 91.76% to $567,000 in 2024, then skyrocketed by 383.97% to $1.1 million in 2025.
  • Its Share-based Compensation was $1.1 million in Q3 2025, compared to $906,000 in Q2 2025 and $507,000 in Q1 2025.